Skip to content Skip to navigation

Intel’s Dishman to lead Precision Medicine Initiative Cohort Program

April 11, 2016
by David Raths
| Reprints
Led Intel’s strategy in areas such as health IT, genomics and personalized medicine

Eric Dishman, vice president of Intel Corp.’s Health & Life Sciences Group, has been named director of the Precision Medicine Initiative Cohort Program. Dishman will lead the National Institutes for Health’s effort to build the PMI landmark longitudinal research study of one million or more U.S. volunteers to expand our ability to improve health and treat disease through precision medicine. 

Dishman was a member of the PMI Working Group that deliberated on the design for the study. He also co-founded some of the nation’s first and largest research/policy programs focused on telehealth, personal health records, independent living technologies for seniors, and behavioral markers for Alzheimer’s, Parkinson’s, diabetes, and heart disease. He is widely recognized as a global leader on home and community-based care and personalized care, as well as for inventing innovation techniques that incorporate ethnography, the systematic study of people and cultures, and other social methods into the design and development of new technologies.

At Intel he was responsible for global strategy, research, platform development, and policy in key areas like health IT, genomics and personalized medicine, consumer wellness, and care coordination technologies. For more than 15 years, he has led Intel’s healthcare strategy and research, including the creation and distribution of Intel’s open platforms and open-source tools to help researchers accelerate scientific discovery ranging from wearable and in-home technologies for movement disorders to big data platforms for cancer genomics.

NIH notes that Dishman also brings the patient experience to equation. After battling a rare form of kidney cancer for 23 years — and advocating personally for more than 1,000 other cancer patients along the way — he became cancer-free thanks to early access to precision medicine that clarified the right treatment plan for him.